- Home
- RVPH vs INKT Comparison
RVPH vs INKT Comparison
Compare RVPH & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVPH
- INKT
- Stock Information
- Founded
- RVPH 2006
- INKT 2017
- Country
- RVPH United States
- INKT United States
- Employees
- RVPH N/A
- INKT N/A
- Industry
- RVPH Biotechnology: Pharmaceutical Preparations
- INKT Medicinal Chemicals and Botanical Products
- Sector
- RVPH Health Care
- INKT Health Care
- Exchange
- RVPH Nasdaq
- INKT Nasdaq
- Market Cap
- RVPH 32.8M
- INKT 28.9M
- IPO Year
- RVPH N/A
- INKT 2021
- Fundamental
- Price
- RVPH $0.39
- INKT $7.28
- Analyst Decision
- RVPH Strong Buy
- INKT Strong Buy
- Analyst Count
- RVPH 5
- INKT 2
- Target Price
- RVPH $9.00
- INKT $37.50
- AVG Volume (30 Days)
- RVPH 3.0M
- INKT 14.7K
- Earning Date
- RVPH 08-13-2025
- INKT 08-12-2025
- Dividend Yield
- RVPH N/A
- INKT N/A
- EPS Growth
- RVPH N/A
- INKT N/A
- EPS
- RVPH N/A
- INKT N/A
- Revenue
- RVPH N/A
- INKT N/A
- Revenue This Year
- RVPH N/A
- INKT N/A
- Revenue Next Year
- RVPH N/A
- INKT N/A
- P/E Ratio
- RVPH N/A
- INKT N/A
- Revenue Growth
- RVPH N/A
- INKT N/A
- 52 Week Low
- RVPH $0.30
- INKT $4.56
- 52 Week High
- RVPH $4.28
- INKT $13.79
- Technical
- Relative Strength Index (RSI)
- RVPH 33.75
- INKT 51.20
- Support Level
- RVPH $0.35
- INKT $6.80
- Resistance Level
- RVPH $0.83
- INKT $7.55
- Average True Range (ATR)
- RVPH 0.06
- INKT 0.34
- MACD
- RVPH -0.02
- INKT -0.01
- Stochastic Oscillator
- RVPH 17.98
- INKT 36.71
About RVPH Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.